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ARTICLE
Identification of the Transcriptional Targets of FOXP2, a Gene
Linked to Speech and Language, in Developing Human Brain
Elizabeth Spiteri, Genevieve Konopka, Giovanni Coppola, Jamee Bomar, Michael Oldham, Jing Ou,
Sonja C. Vernes, Simon E. Fisher, Bing Ren, and Daniel H. Geschwind
Mutations in FOXP2, a member of the forkhead family of transcription factor genes, are the only known cause of
developmental speech and language disorders in humans. To date, there are no known targets of human FOXP2 in the
nervous system. The identification of FOXP2 targets in the developing human brain, therefore, provides a unique tool
with which to explore the development of human language and speech. Here, we define FOXP2 targets in human basal
ganglia (BG) and inferior frontal cortex (IFC) by use of chromatin immunoprecipitation followed by microarray analysis
(ChIP-chip) and validate the functional regulation of targets in vitro. ChIP-chip identified 285 FOXP2 targets in fetal
human brain; statistically significant overlap of targets in BG and IFC indicates a core set of 34 transcriptional targets
of FOXP2. We identified targets specific to IFC or BG that were not observed in lung, suggesting important regional and
tissue differences in FOXP2 activity. Many target genes are known to play critical roles in specific aspects of central
nervous system patterning or development, such as neurite outgrowth, as well as plasticity. Subsets of the FOXP2 tran-
scriptional targets are either under positive selection in humans or differentially expressed between human and chim-
panzee brain. This is the first ChIP-chip study to use human brain tissue, making the FOXP2-target genes identified in
these studies important to understanding the pathways regulating speech and language in the developing human brain.
These data provide the first insight into the functional network of genes directly regulated by FOXP2 in human brain
and by evolutionary comparisons, highlighting genes likely to be involved in the development of human higher-order
cognitive processes.
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Spoken language and written language are uniquely hu-
man traits with a significant but complex genetic com-
ponent. As with other developmental processes, the study
of rare Mendelian forms of language or speech disorders
provides an efficient means to begin to understand the
molecular basis of human speech and language.1 FOXP2
was identified as involved in speech and language when
affected members of the “KE” family were found to carry
a mutated allele, and an unrelated individual was found
to carry a balanced translocation with a break in FOXP22
(causing speech-language disorder 1 [SPCH1 {MIM
602081}]). Its role in speech and language was reiterated
when an additional mutation that caused a truncation of
FOXP2 was identified in a family with speech and lan-
guage deficits.3 Individuals with FOXP2 mutations have
dominantly inherited verbal dyspraxia and linguistic and/
or grammatical difficulties.2,4,5 Additionally, patients with
FOXP2 mutations have demonstrated developmental ab-
normalities of the basal ganglia (BG) and inferior frontal
cortex (IFC).6,7 FOXP2 expression overlaps with perisyl-
vian frontal and temporal regions, including the inferior
frontal gyrus (Broca’s region), but also extends more
broadly to suggest a role in complex sensory motor in-
tegration involving auditory vocal learning,8,9 as well as
mirror neuron system function, which is highly evolved
in primates and disrupted in autism.10,11
FOXP2 belongs to a family of proteins that contain a
forkhead DNA binding, or “winged helix,” domain, a re-
gion responsible for DNA binding that is found in tran-
scription factors.2 FOXP2 also contains a transcriptional
repression domain including a zinc-finger motif in the N-
terminal region12 and has been shown to interact with the
corepressor protein C-terminal binding protein 1.13 Foxp1,
Foxp2, and Foxp4 have been demonstrated to form het-
ero- and homotypic dimers that are important for their
transcriptional activity.13 The expression patterns of
FOXP1 and FOXP2 are not identical8; therefore, in some
cases, the proteins may be forming heterotypic dimers,
whereas, in others, they may act alone.13 Foxp2, the mouse
orthologue of FOXP2, has been proposed to be an im-
portant regulator of proximal versus distal epithelial dif-
ferentiation in the lung, on the basis of in vitro repression
of the mouse CC10 promoter and human SP-C promoter.12
Additionally, other members of the forkhead-box (FOX)
family of transcription factors are well established as tran-
scriptional repressors or activators involved in develop-
ment.14–16 However, the role of FOXP2 in the brain and
its transcriptional targets remain to be elucidated.
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Figure 1. FOXP2 antibody detection of human brain and lung FOXP2 expression. A, Peptide used as an antigen to create the FOXP2
antibody aligned against the amino acid sequence of FOXP2 and family members FOXP1 and FOXP4. Protein from MRC5 cells transfected
with expression vectors containing FOXP2 isoforms I and III and FOXP1 and FOXP4 transcripts were run on an SDS-PAGE gel, were
transferred to PVDF membrane, and were hybridized with polyclonal anti-FOXP2 antibody (lanes 1–4). FOXP1 and FOXP4 were also
hybridized with protein-specific antibodies (lanes 5 and 6) as a positive control for protein expression. B, FOXP2 isoform I protein
immunoprecipitated from lung, BG, and IFC regions run on an SDS-PAGE gel, transferred to PVDF membrane, and hybridized with
polyclonal anti-FOXP2 antibody (Ab).
Previous analyses of amino acid changes in FOXP2
across species indicate that FOXP2 has undergone accel-
erated evolution in humans.17,18 The most parsimonious
explanation for the observed acceleration is positive se-
lection of FOXP2 in humans, since there is no evidence
of an increase in the mutation rate or purifying selection.
Thus, the study of FOXP2 provides a potentially powerful
avenue for investigations into the molecular and physical
adaptations that allowed for the development of speech
and language in humans. Language is a complex trait and
necessarily involves the interaction of many genes,1 some
of which may have coevolved. Since FOXP2 is a transcrip-
tion factor, identification of its transcriptional targets in
the brain and the assessment of their evolution would
provide an important advance by elucidating the molec-
ular pathways involved and potential evidence of their
adaptive evolution.
Here, using chromatin immunoprecipitation (ChIP) fol-
lowed by hybridization of the precipitated DNA to human
promoter arrays (hereafter, “ChIP-chip”), we have iden-
tified targets of FOXP2 in vivo in both the BG region and
the IFC of the human fetal brain. A subset of ChIP-chip–
identified targets were confirmed by ChIP–quantitative
PCR, and the functional consequence of FOXP2 binding
to target promoters was demonstrated by FOXP2 over-
expression in vitro. This study, along with that by Vernes
et al.,19(in this issue) provides the first insight into the direct
functional targets of FOXP2 during human brain devel-
opment, as well as a core set of genes for further explo-
ration into the genetic basis of human speech and
language.
Material and Methods
Antibody Production
A 15-mer amino acid sequence was chosen from the C-terminal
region of FOXP2. A FOXP2 antibody was made against the 14-aa
sequence EDLNGSLDHIDSNG (fig. 1) in the C-terminal region of
FOXP2. The 14-aa peptide was chosen on the basis of its anti-
genicity (DNASTAR) and dissimilarity between family members
FOXP1 and FOXP4 (fig. 1). Similarity of the amino acid sequence
to other proteins was excluded by comparisons with family mem-
bers FOXP1 and FOXP4, as well as by protein blast (blastp) anal-
ysis (BLAST). The peptide was conjugated to keyhole limpet he-
mocyanin, and rabbits were immunized with the peptide and
complete Freund’s adjuvant (Sigma-Genosys). Antibody was pu-
rified on an affinity purification column with the peptide (Sigma-
Genosys).
Western-Blot Analysis
MRC5 or SH-SY5Y cells were lysed in hypotonic buffer (10 mM
Tris-Cl, 10 mM KCl, 0.1 mM EDTA, and 0.1 mM ethylene glycol
tetraacetic acid [EGTA]) and were sonicated briefly. Cell debris
was removed by centrifugation. Protein was run on a 7.5% SDS-
PAGE gel and was transferred to a polyvinylidene fluoride (PVDF)
membrane. The membrane was blocked with 5% milk in PBS-
Tween for 2 h. The corresponding lanes were then incubated with
FOXP2 in-house antibody (1:5,000 dilution), FOXP1 in-house an-
tibody (1:10,000 dilution), FOXP4 ab17726 Abcam antibody (1:
1,000 dilution), or FLAG F3165 Sigma antibody (1:10,000 dilu-
tion) in 5% milk in PBS-Tween overnight at 4C. Blots were
washed and incubated with 1:10,000 dilution of horseradish per-
oxidase–conjugated anti-rabbit or anti-mouse secondary anti-
body (Jackson ImmunoResearch Laboratories) and then were ex-
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posed to SuperSignal West Pico Chemiluminescent Substrate
(Pierce) in accordance with the manufacturer’s directions.
Tissue Samples
Human tissue samples were obtained from the National Institute
of Child Health and Human Development (NICHD) Brain and
Tissue Bank for Developmental Disorders under contracts N01-
HD-4-3368 and N01-HD-4-3383 (lungp University of Maryland
Brain Bank [UMB] number 1926 [18 gestational wk {GW}]; BGp
UMB number 1664 [19 GW], UMB number 1888 [19 GW], and
UMB number 1876 [20 GW]; IFC p UMB number 638 [16 GW],
UMB number 899 [18 GW], and UMB number 1876 [20 GW]).
FOXP2 targets in human fetal brain during midgestation (16–20
GW) were investigated because this time corresponds to the peak
period of neuronal migration, differentiation, and cortical re-
gionalization and is a time of high FOXP2 expression.8,9,20
ChIP
ChIP was performed as described elsewhere.21 For each experi-
ment, 0.6 g of human tissue was used. Tissue was finely minced
in PBS on ice, and the cross-linking reaction was subsequently
performed for 15 min at room temperature. Nuclei were isolated,
and DNA was sonicated in 1 ml of buffer (1 mM EDTA, 0.5 mM
EGTA, and 10 mM Tris-HCl) to DNA fragments that were ∼0.2–1
kb in size. Then, 100 ml of Protein A beads were mixed with 10
mg of FOXP2 antibody overnight. Nuclear lysate was hybridized
to the beads overnight. Beads were then washed five times with
RIPA buffer (50 mM Hepes, 1 mM EDTA, 0.7% deoxycholic acid,
1% NP-40, and 0.5 M LiCl), and protein-DNA complexes were
eluted (50 mM Tris, 10mM EDTA, and 1% SDS) at 65C for 12
min. The cross-linking reaction was reversed at 65C overnight
(50 mM Tris, 10 mM EDTA, and 1% SDS). The ends of the DNA
were blunted with T4 DNA polymerase (New England Biolabs)
for 20 min at 12C. DNA was ligated to annealed linkers (oJW102,
GCGGTGACCCGGGAGATCTGAATTC, and oJW103, GAATTCA-
GATC) at 16C for 16 h. ChIP and input DNA were amplified by
PCR, with 1 mM deoxynucleotide triphosphates, 2 U Taq (Qia-
gen), and 1 mM oJW102. Cycling conditions were 1 cycle for 5
min at 72C; 95C for 2 min; 24 cycles at 95C for 1 min, 60C
for 1 min, and 72C for 1 min; and 1 cycle for 5 min at 72C.
For some ChIPs, a second and third round of PCR was performed
to obtain enough DNA.
Labeling and Hybridization
A total of 200 ng of purified PCR product was labeled with Cy5
(ChIP DNA) and Cy3 (input DNA) with BioPrime DNA labeling
system (Invitrogen) at 37C for 16 h. Human promoter arrays
(Aviva Systems Biology)22 were hybridized with 2 mg of each la-
beled ChIP and input DNA.
Microarray and Data Analysis
Arrays were scanned on a GenePix 4000B (Molecular Devices),
and image analysis was performed with GenePix Pro 6.0. Three
independent biological replicates were analyzed for BG and IFC;
two independent biological replicates were analyzed for lung.
Poor-quality spots were flagged by GenePix Pro 6.0. Background
was determined on a spot-by-spot basis. Data analysis was per-
formed using R with Bioconductor23 packages Limma and Marray.
The quality of arrays was determined on the basis of signal plots
before normalization. Spots whose signal intensities were twofold
greater than the local background were considered present. Me-
dian normalization was performed. Data have been deposited
into NCBI Gene Expression Omnibus (GEO) and can be accessed
with accession number GSE8547.
Gene Ontology (GO) Analysis
Target genes with an M score 10.5 and a P value of 1.05 were
analyzed using DAVID.24,25 The Fisher exact test was used, with
all array genes as background.
Stable and Transient-Overexpression Cell Lines
cDNA was transcribed from RNA isolated (Qiagen) from human
fetal brain by use of the Superscript First-Strand Synthesis System
(Invitrogen). FOXP2 was amplified via PCR with forward primer
FOXP2-1F(BamHI) (5′-aaggatccatgatgcaggaatctgcgac-3′) and re-
verse primer FOXP2-1R(EcorI) (5′-ccgaattcttccagatcttcagataaa-
ggc-3′). FOXP1 was amplified with forward primer Foxp1kozakF
(5′-caccatgatgcaagaatctgggac-3′) and reverse primer Foxp1w/otagR
(5′-tcactccatgtcctcgtttac-3′). A FOXP4 clone was obtained from
Open Biosystems (MHS1010-9204774). Products were cloned into
a pEF6/V5-His TOPO TA vector for transient expression in MRC5
cells. MRC5 cells were transiently transfected with linearized
clones with Lipofectamine 2000 (Invitrogen) for 24 h. For stable
transfection in SH-SY5Y cells, PCR products were cloned into the
pCMV-Tag4A vector (Stratagene) with three C-terminal FLAG
tags. SH-SY5Y cells were transfected with linearized clones either
with the FOXP2 insert or without (vector only) by use of Lipo-
fectamine 2000 (Invitrogen) and were selected for stably trans-
fected cells with 1.428 mg/ml Geneticin (Invitrogen) for 15 d.
The antibiotic was removed at least 48 h before harvesting for
quantitative PCR experiments. Seven passages of each cell line
were used as biological replicates.
Real-Time PCR
RNA was extracted using RNeasy Mini Kit (Qiagen) following the
manufacturer’s directions. DNA was removed by digestion with
RNase-free DNase (Qiagen). A quantity of 1.2–5 mg was used in a
reaction to synthesize cDNA with oligo dT primers. Quantitative
real-time PCR was performed on an ABI 7900HT (Applied Bio-
systems) with SDS 2.1 software. The reaction mix contained iTaq
SYBR Green Supermix (Bio-Rad) and 0.3 mM of each primer. Cy-
cling conditions were 50C for 2 min and 95C for 3 min, followed
by 45 cycles at 95C for 15 s and 58C for 45 s, and, finally, 95C
for 15 s, 60C for 20 s, and 95C for 15 s.
ChIP-PCR
ChIP was done as described above by use of anti-FOXP2 (rabbit
polyclonal [Abcam]) or anti-FLAG (mouse monoclonal [Sigma])
antibodies. PCR was performed using either SYBR Green Supermix
(Bio-Rad) or Taq (Qiagen) and the following primers: for ANK1,
5′-ccccctccttaggaaacaaa-3′ and 5′-agcccagagttggacatcag-3′; for
CALCRL, 5′-tcactctttcccaccttgct-3′ and 5′-gaaacattgccaaactatatga-
gaa-3′; for CDH1, 5′-ctcgacacccgattcaaagt-3′ and5′-gcgtgactttggtgg-
aaaac-3′; for LBR, 5′-taaagctgggaggtgctgtc-3′ and5′-ggctgctgtaggctt-
gagag-3′; for KCNJ15, 5′-ccagtaggcaaatccttcca-3′ and 5′-ggggat-
agaaattcgggtgt-3′; for PIR51, 5′-cagtccaagtgcccctatgt-3′ and 5′-ggaa-
ctacccacctcacagg-3′; for PPP2R1B, 5′-acaacagaaggcaccattcc-3′ and
5′-ccgctcagactcaaacttcc-3′; for TGM2, 5′-tggctgtgtcaggctgtatc-3′
and 5′-acacagagagcagacgcaga-3′; and, for TNNI1, 5′-tgctggtttcactc-
agttgg-3′ and 5′-aatgcacacaacaggcacat-3′.
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Table 1. Summary of Results for All
Identified Target Genes
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Comparison of Gene-Expression Levels and Estimates
of Protein-Sequence Divergence Rates between Humans
and Chimpanzees
Gene-expression levels in human and chimpanzee cerebral cortex
were determined by combining microarray data from three in-
dependent studies.26–28 To identify probes common to both spe-
cies, megablast (BLAST) was used to align all probes from the
Affymetrix HGU95Av2 microarray to the human genome (build
34) and the chimpanzee draft genome. Any probe without a per-
fect match in both species (∼1/4) was masked during the calcu-
lation of expression values (GCOSv1.2 [Affymetrix]). In addition,
only probe sets with six or more matching probes were retained
for subsequent analyses ( of 12,625 sets). For each ar-np 11,768
ray, expression values were scaled to an average intensity of 200
(GCOSv1.2 [Affymetrix]). Two samples, “Hs3_MFG” and “Pt4_FP”
from the study of Caceres et al.,26 were identified as outliers and
were removed from the analysis. Technical replicates were aver-
aged, followed by biological replicates (i.e., different cortical sam-
ples from the same individual). After averaging, there were 11
unique human and 8 unique chimpanzee individuals in the data
set (two of the chimpanzees from these studies26–28 were identical).
Quantile normalization26 was then performed, and data were log
transformed. Gene-expression levels were compared between the
species by use of a Bayesian t test via the “bayesreg” R package,
with the settings betaFit p 1, winSize p 101, and conf p 10.
Estimated rates of protein-sequence divergence between humans
and chimpanzees were obtained from the study of Khaitovich et
al.29
Results
The FOXP subfamily of transcription factors have rela-
tively high homology among themselves, so it was im-
portant to generate an immunoreagent that would meet
the specificity and efficiency requirements of ChIP. We
produced a high-affinity FOXP2 polyclonal antibody on
the basis of immunization with a relatively divergent re-
gion near the C-terminus (fig. 1). Since isoform III does
not share the N-terminus with isoforms I and II, this C-
terminal moiety provided the additional benefit of per-
mitting detection of all FOX domain–containing isoforms
of FOXP2. No cross-reactivity was detected for FOXP1 or
FOXP4, and the antibody detected two major FOXP2 iso-
forms, designated isoform I and III (GenBank accession
numbers NP_055306 and NP_683697 or NP_683698) as
predicted (fig. 1). A protein of ∼80 kDa was immunopre-
cipitated from human fetal brain regions and lung (fig. 1).
Immunohistochemistical staining of mouse brain by use
of this antibody reflects previously described patterns of
postmitotic neuronal staining in the cortex and BG (data
not shown).20
Identification of Core FOXP2 Targets by In Vivo ChIP-Chip
in Fetal Human Brain
Given previous data suggesting adaptive evolution of
FOXP2 in humans17,18 and its involvement in human
higher cognitive functions, we were interested in eluci-
dating FOXP2 targets in the human brain. We performed
ChIP-chip experiments on human fetal brain during mid-
gestation, which corresponds to the peak period of neu-
ronal migration, differentiation, and cortical regionaliza-
tion and is a time of high FOXP2 expression.8,9,20 The two
regions we chose, one cortical (IFC) and one subcortical
(BG), are part of a parallel-distributed circuitry that,
among other functions, is involved in language and
speech,30,31 express high levels of FOXP2 during this period
of development,8 and are sites of abnormalities in patients
with FOXP2 mutations.32 Thus, FOXP2 targets identified
within these regions during human brain development
would be particularly germane to the understanding of
the molecular circuitry involved in the development of
these regions and their relationship to speech and lan-
guage functions. Furthermore, the importance of this pe-
riod for key aspects of the development of the human
cerebral cortex is also highlighted by previous studies that
demonstrate key elements of patterning—including brain
asymmetry, a structural correlate of language—that occur
during this time.31,33
We used rapidly frozen tissue stored at 80C, with
short postmortem intervals, to optimize the likelihood of
detecting regions of DNA bound by FOXP2 (see the “Ma-
terial and Methods” section). ChIP products from three
independent replicates were hybridized onto Aviva Sys-
tems Biology cDNA promoter arrays containing ∼6,000
DNA fragments from potential regulatory regions, which
were initially validated in the first genomewide ChIP-chip
studies (see the “Material and Methods” section).22 Al-
though this is not a whole-genome microarray, it has been
validated in several important ChIP studies and provides
a very solid cross-section of genes.34,35 Since no FOXP2
targets had been previously identified, we reasoned that
this platform would provide a good cross-section of
targets.
We identified 175 targets in BG and 144 targets in IFC,
using conservative criteria (see the “Material and Meth-
ods” section and table 1). The overlap between the two
regions was highly significant, with 24% of IFC genes over-
lapping with BG genes (hypergeometric probability p !
). An additional set of genes identified as re-226.767# 10
gionally specific in either BG (141 genes) or IFC (110
genes) were identified (fig. 2). These genes may represent
specific regional targets of FOXP2 regulation.
FOXP2 Targets in Lung versus Brain
Murine Foxp2 has been shown to repress the promoter of
the human lung-epithelial specific gene SP-C in vitro.12
Since Foxp2 has been reported as a transcriptional re-
pressor that is expressed in the developing lung of mice,12
we were interested to see, which, if any, of the identified
Figure 2. Transcriptional targets of FOXP2 identified by ChIP-chip assay
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Figure 3. Distribution of FOXP2 targets identified among tissue
regions. Shown are overlapping and tissue-specific targets of the
175 BG, 144 IFC, and 192 lung target genes among the three
experiments. The P values based on the hypergeometric distri-
bution show highly statistically significant overlap between the
tissues.
Figure 4. Confirmation of identified FOXP2 targets by ChIP-PCR
from SH-SY5Y cells overexpressing FLAG-tagged FOXP2 (A) or IFC
(B). A, Promoters of three FOXP2 targets showing enrichment of
FLAG-tagged FOXP2 at their promoters compared with control im-
munoprecipitations (IPs). No enrichment occurred at a lung-spe-
cific promoter, ANK1, or in a gene that was not a FOXP2 target,
CDH1. B, Promoters of three FOXP2 targets showing enrichment of
endogenous FOXP2 compared with control IPs. Also shown is an
example of an IFC target, PIR51, that did not show confirmation
by ChIP-PCR. No enrichment is seen when primers are used for the
ANK1 promoter or CDH1 gene. No Abp no addition of anti-FOXP2
antibody.
targets were potentially more-specific targets in the de-
veloping brain relative to lung, a non-CNS tissue express-
ing high levels of FOXP2 during development. Further-
more, no studies of targets of FOXP2 have been published
from any human tissue, so even overlapping targets would
be of general interest and would serve as a core set of non–
tissue-specific FOXP2-regulated genes. We performed
ChIP-chip in human fetal lung at 18 GW and identified
192 targets (table 1). There was 47% and 37% overlap
between genes identified in lung and BG and in lung and
IFC, respectively (fig. 3), providing further confidence in
these genes as robust FOXP2 targets. Subtraction of the
lung-enriched genes from the CNS data sets yielded 84
BG-specific genes and 83 IFC-specific genes (fig. 3 and ta-
ble 1). In addition, there were eight targets found in both
BG and IFC that were not enriched in lung. These highest-
confidence brain-enriched targets include FGF8, which is
a key effector of cortical patterning in mammals,36 and
HOXB5 and HOXB7, members of the homeobox family of
transcription factors, many of which are already known
to be involved in CNS patterning.37,38
To provide independent validation of the array results,
we checked a cross-section of the putative FOXP2 targets
by ChIP-PCR, as is now standard.34,35,39,40 We used a second
commercial antibody to FOXP2 to validate brain tissue
and an antibody against the FLAG epitope in a neuronal
cell line. For the cell-line confirmation, the neuronal cell
line SH-SY5Y was stably transfected with FOXP2 isoform
I with three C-terminal FLAG tags (see the “Material and
Methods” section). Using either real-time quantitative or
semiquantitative PCR, we assessed seven nervous-system
targets in vitro and were able to confirm enrichment of
FOXP2 occupancy at the promoters of all these genes (fig.
4 and data not shown). In contrast, the promoter of one
lung target tested, ANK1, was not pulled down in these
neuronal cells and served as a negative control; even
though the level of expression of ANK1 changed in SY5Y
cells with overexpressed FOXP2, it is likely a result of in-
direct regulation by FOXP2 and not direct binding. Al-
though tissue was a limiting factor, we were able to test a
subset of FOXP2 CNS targets in fetal brain tissue by ChIP-
PCR and confirmed three of five promoters examined, pro-
viding a secondary level of confirmation for these targets
(fig. 4 and data not shown).
In Vitro Functional Validation of FOXP2 Targets
To provide some functional evidence of target regulation,
we assessed the effect of FOXP2 overexpression in a neu-
ronal cell culture system on identified FOXP2 targets. SH-
SY5Y cells were stably transfected with FOXP2 isoform I
with three C-terminal FLAG tags, and a population of sta-
bly transfected cells was used for the experiments at sev-
eral different passages (fig. 5). Cells stably transfected with
empty plasmid were used as a baseline control for com-
parison. Immunoblotting of the two cell lines for both
FOXP2 and FLAG revealed robust expression of FLAG-
tagged FOXP2 in the cell line transfected with FOXP2,
compared with no expression in the cells transduced with
the empty vector (fig. 5A and data not shown). This cell
line provides an appropriate vehicle for overexpression
studies, since FOXP1 is natively expressed in these cells,
whereas FOXP2 is not detectable.4
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Figure 5. FOXP2 overexpression confirming functional regulation
of targets by FOXP2. A, Cell lysate from SH-SY5Y cells transfected
with empty vector or FOXP2 isoform I, run on an SDS-PAGE gel
and transferred to PVDF membrane. The membrane was hybridized
with anti-FLAG antibody and anti-GAPDH antibody. B, Nineteen
genes tested by qRT-PCR. The average of seven replicates and SEMs
are indicated. Genes with a down-regulation in expression are
shown in red, whereas those with a positive change in gene ex-
pression are shown in blue. Genes with significant difference in
expression between control and FOXP2-overexpressing cells are in-
dicated with an asterisk (*) ( , by Student’s t test).P ! .05
The majority of target genes investigated were chosen
randomly, although a few were selected on the basis of
their enrichment in all tissues studied (NOS1, CALCRL,
PM5, and GDF5). Real-time quantitative RT-PCR (qRT-
PCR) for 19 genes was performed on seven biological rep-
licates of both control cells and cells overexpressing
FOXP2. qRT-PCR analysis demonstrated that the majority
of FOXP2 target genes identified (11 of 19) had at least a
25% change in expression with FOXP2 isoform I over-
expression (fig. 5). Three genes, TAGLN, CALCRL, and
CER1, showed up-regulation after overexpression of
FOXP2, whereas DPAGT1 showed a trend toward increased
expression (fig. 5). To test the reproducibility of the results,
two genes, TNN1 and NUDT1, were examined using two
different sets of primers in a blinded fashion. Both primer
sets gave very similar results for each gene, indicating high
specificity for the assay (data not shown). By use of a two-
tailed paired t test, five of the genes had statistically sig-
nificant fold changes between control and FOXP2-over-
expressing cells. These genes were CALCRL, NOS1, LBR,
KCNJ15, and ANK1. Accordingly, all these genes had
changes 11.5 fold and were contained within the top-
seven most changed genes. Interestingly, two of these
genes, NOS1 and CALCRL, represent two of the genes en-
riched in all tissues by ChIP-chip and, as mentioned
above, were selected a priori for this reason. Thus, we can
conclude that the levels of at least 26% of the genes iden-
tified as targets of FOXP2 can be altered by manipulating
expression of FOXP2 in a neuronal cell line. These data,
confirming slightly more than 25% of targets examined
in vitro, are consistent with those of other published stud-
ies, in which 20%–35% of the targets are typically con-
firmed in this manner.39–43
FOXP2 Binding Sites Sequence in Candidate Genes
We next determined whether the promoter regions of can-
didate genes present on the Aviva array contain putative
FOXP2 binding sites. Since double-stranded PCR products
were spotted onto the array, the binding site could lie in
either strand, so we examined both strands. We inspected
the sequences of identified candidate targets for the
FOXP2 binding site CAAATT or the core FOXP2 binding
site AAAT.44 The sequence from 323 of 367 potential tar-
gets identified by ChIP-chip was examined for binding
sites, and 95% (307 genes) were found to contain at least
one AAAT core FOXP2 binding site, whereas 106 con-
tained at least one CAAATT binding site (table 1). Since
the FOXP1 binding site (TATTT[A/G]T) has been shown
to be a possible FOXP2 binding site,4,45 we also searched
for the presence of a FOXP1 binding site. A total of 82
genes were found to have at least one FOXP1 binding site
(table 1). All genes tested by overexpression of FOXP2 were
found to have at least one copy of the core-binding site
(AAAT), and most had multiple sites. HSPB7, CER1,
CALCRL, ANK1, LBR, and KCNJ15, which showed direc-
tional changes in expression following overexpression of
FOXP2, were also found to have at least one CAAATT bind-
ing site. Additionally, NOS1, which showed a large, sta-
tistically significant decrease in expression, and CALCRL,
which showed a significant increase in expression after
FOXP2 overexpression, as well as GDF5, were found to
have a FOXP1 binding site present. Comparing this en-
richment of FOXP2 sites within the target genes identified
on the array with an equivalent number of random pro-
moter sequences from Ref Seq genes showed a statistically
significant enrichment for all sequences identified in BG
as a group ( , by x2 with Yates correction), which wasP ! .05
more significant for the more stringent canonical CAAATT
site in BG targets ( , by x2). The targets identifiedPp .007
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Figure 6. GO categories of in vivo targets, revealing tissue specificity of target pathways. FOXP2 target gene lists from either the CNS
(BG and IFC) or lung were analyzed for significantly enriched GO categories by use of DAVID Bioinformatics Resources. Categories were
considered significantly enriched if at least three genes were in one category with a P value .05. Significant CNS targets with a known
molecular function fall into six categories (A), whereas lung targets can be classified into three categories (B), none of which overlap
with the CNS results. Significant CNS targets with a known biological function are grouped into 11 categories (C). There were no
significant biological function categories for lung-specific targets.
in IFC and lung showed the same trend as BG but did not
reach significance.
Functional Annotation
To investigate whether FOXP2 target genes belong to
functional categories that provide insight into the role
of FOXP2, we performed GO and pathway analysis on
target genes, using the DAVID Bioinformatics Resources.24
Gene targets identified in BG or IFC were grouped together
as “CNS-specific” genes and were compared with and con-
trasted to “lung-specific” genes. We focused on GO cate-
gories of level three or higher, containing at least three
genes and having a P value .05 by Fisher’s exact test.
CNS-specific genes were significantly enriched in six cat-
egories of molecular function, and the lung genes were
enriched in three categories that did not overlap with
those found in the CNS gene set (fig. 6). The CNS-specific
genes were enriched for 11 biological-function GO cate-
gories, whereas the lung data set did not have any sig-
nificant categories grouped according to biological
function.
Several intriguing CNS-enriched GO categories were
identified: morphogenesis (TIMELESS, WNT1, SOX13,
HOXB5, and FGF8), intracellular signaling cascades
(CDC42BPB, GABBR1, CCKAR, RP26KA2, and RRAS), and
cation homeostasis (GALR2, RYR3, and CCKAR). Focusing
this analysis on those genes contained within significantly
enriched GO categories in the CNS allowed us to uncover
FOXP2 targets with potential roles in neural development
and to strengthen the hypothesis of FOXP2 as a crucial
player in signaling cascades regulating this critical epoch.
Salient examples of FOXP2 targets previously shown to
be important for CNS development models include
WNT146,47 and RPS6KA2, also known as RSK3, which is
highly expressed in the cortical primordium.48 Mutations
in a related family member of RSK3, RSK2, lead to Coffin-
Lowry syndrome (MIM 303600), which is associated with
cognitive abnormalities.49
Another critical pathway downstream of FOXP2 in the
IFC appears to be neurite outgrowth and axonal mor-
phology, including calcium-mediated growth cone dy-
namics (e.g., GALR2, POU4F2, RRAS, and RYR3).50–54 Fur-
ther support for the role of FOXP2 transcriptional targets
in dynamic regulation of neuronal structure was obtained
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Table 2. Fourteen Genes with Ka/Ki
or Ka/Ks 11.0
Gene
GenBank
Accession
Number
Positive Selection
Ka/Ki Ka/Ks
CA4 NM_000717 .6937 1.5476
CD7 NM_006137 .7805 1.5375
CER1 NM_005454 .5913 1.7308
FCGR2A DQ894525 .7127 2.8529
GPR21 NM_005294 NA 1.3871
HESX1 NM_003865 .5971 75
LBR NM_002296 NA 1.0833
MEOX1 NM_004527 NA 52
NDUFA2 NM_002488 1.6458 1.2958
PGLYRP NM_005091 1.8051 .5485
PIR51 NM_006479 NA 56
PRG4 NM_004758 2.4455 .5826
RBP2 NM_004164 .9006 106
ZNF43 NM_003423 NA 1.5405
NOTE.—Estimated rates of protein-sequence
divergence between humans and chimpanzees
were obtained from the study by Khaitovich et
al.29 NA p not available.
Table 3. Summary of Evolutionary Data
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
using Ingenuity pathway-analysis software to analyze the
34 core CNS targets identified in both BG and IFG. In-
genuity identified several functions of neuronal activity
significantly enriched, including branching of dendrites
(NOS1 and CRH), mobilization of calcium (CALCRL, CD5,
and PRLH), quantity of calcium (EPOR and CRH), and
learning (CRH and EPOR) (data not shown). These data
also suggest a possible function for FOXP2 signaling cas-
cades in activity-based (e.g., long-term potentiation) mod-
eling of neural connections, in addition to its role in
development.
Possible Positive Selection of Several FOXP2 Targets
in Humans
FOXP2 is clearly involved in multiple functions not re-
lated to human higher cognitive functions, including sen-
sorimotor integration and vocal learning in birds8,55 and
lung development outside the CNS.12 It would therefore
be useful to identify a list of targets that most likely con-
tribute to the development of higher cognitive speciali-
zations.11 We hypothesized that, given the genetic com-
plexity of a highly advantageous trait such as human
language, positive selection may be working on FOXP2
target proteins in addition to FOXP2 itself.17,18 We rea-
soned that identification of FOXP2 target genes poten-
tially under positive selection will enrich for those target
genes more likely to be involved in language develop-
ment. We analyzed our data with respect to published
estimates of protein sequence divergence (Ka/Ki and Ka/
Ks) for 1,168 genes with available data.29
Ka measures the rate of nonsynonymous nucleotide
substitutions, Ki measures the rate of nucleotide substi-
tutions in interspersed repeats within a 250-kb window
centered around each gene, and Ks measures the rate of
synonymous substitutions. Low Ka/Ki or Ka/Ks values sug-
gest strong purifying selection (deleterious mutations),
whereas elevated Ka/Ki values suggest accelerated evolu-
tion via positive selection, or relaxation of constraint.29
Typically, a value 11.0 is indicative of acceleration.56 Four-
teen genes identified as FOXP2 targets in either BG, IFC,
or lung had Ka/Ks or Ka/Ki 11.0 (table 2). As a whole, these
genes are potential key FOXP2 targets that, by virtue of
their sequence divergence, show evidence of accelerated
evolution. Remarkably, this list includes genes such as
NDUFA2, which is part of the electron transport chain, a
pathway identified to be under potential adaptive evo-
lution in humans by comparative gene-expression studies
in brain.57,58 It also includes a number of other genes im-
plicated in vertebrate forebrain patterning, including
HESX1 and CER1. Remarkably, four of the FOXP2 targets,
HESX5, MEOX1, PIR51, and RBP2, have Ka/Ks values 150.29
Genes with evidence of accelerated evolution, which is
likely to be indicative of positive selection in humans,
comprise a key cohort potentially related to human cog-
nitive specializations integrated by the BG and IFC, in-
cluding speech and language.
Differential Expression of Several FOXP2 Targets
between Chimpanzee and Human Brain
Although measures of protein-sequence divergence mea-
sure one key metric of function relevant to evolution, they
do not consider additional changes in promoter or other
regions that might alter gene expression, another dimen-
sion relevant to brain evolution.58,59 This is especially im-
portant because FOXP2 is a transcriptional regulator, and
one might expect its targets to exhibit differential ex-
pression between evolutionarily divergent species. There-
fore, we performed a meta-analysis of primate-human
gene-expression data, to identify genes differentially ex-
pressed in the brains of humans and nonhuman primates,
using three published data sets26–28 to insure identification
of the most robust changes in expression (see the “Ma-
terial and Methods” section). This was essential since each
study was comprised of only a few individuals. We iden-
tified 47 FOXP2 target genes that were differentially ex-
pressed between human and chimpanzee brains, includ-
ing one of the genes whose coding region was also under
positive selection, FCGR2 (table 3).
Among FOXP2 in vivo targets showing primate-human
differential expression were a number of genes encoding
transcription factors involved in neural development, in-
cluding PAX3 and HOXB5, and a number of other genes
encoding known CNS patterning and guidance molecules,
such as EPHX2, ITGB3, and SEMA3B.60 Several genes re-
lated to neural transmission, including neurotransmitter
receptor genes GFRA1 and GRIK1, were also identified
among this cohort. When combined with the analysis of
sequence evolution, these data suggest a potential role of
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specific genes in human cognition by identifying genes
with differential expression at the mRNA level or that are
potentially under positive selection in humans.
Discussion
Here, we identify FOXP2 targets in vivo for the first time,
providing an initial transcriptional network downstream
of this gene known to be involved in human higher cog-
nition and vocal-motor learning. We used previously pub-
lished, well-validated ChIP-chip methods21,22 and, in
addition, performed extensive functional validation. Al-
though the majority of genes were repressed by FOXP2,
we were able to identify a subset of genes that appear to
be activated by FOXP2 at the transcriptional level, indi-
cating that FOXP2 can act as a transcriptional activator
in some contexts. Further, we show that some of the genes
show evidence of accelerated evolution and thus may be
under positive selection in humans, or they are differen-
tially expressed between chimpanzee and human brain,
providing support for their potential role in higher cog-
nition and language. Some FOXP2 targets, such as FGF8
and PAX3, have known roles in cerebral cortical pattern-
ing, immediately connecting FOXP2 transcriptional reg-
ulation to brain patterning during development.36,61
FOXP2 Targets and Transcriptional Activity
FOXP2 promoter binding demonstrated by ChIP-chip
across multiple samples and multiple independent repli-
cate experiments provides strong support for the targets
identified. By comparing targets identified in different
CNS tissues, we were able to identify a large set of core
nervous-system targets with genes specific to the different
regions. Further, we confirm a cross-section of targets, us-
ing ChIP-PCR in vitro and in vivo with use of a second
antibody, an additional level of confirmation.
We also note that a subset of FOXP2 targets were iden-
tified in two brain regions and not in lung. Although we
hypothesize that some of these may be CNS-specific
FOXP2 targets, it remains possible that some could be tar-
gets in other nonneural tissues, a question that can be
explored in subsequent studies. Additionally, this distinc-
tion of CNS specificity does not necessarily make these
genes higher priorities for further study than genes iden-
tified in lung. Many FOXP2 targets were also identified in
the lung, including several genes known to play important
roles in nervous-system development or maturation, such
as MEF2D, GDF5, POU4F3, SEMA3B, A2BP1, and PAX3,
which is correlative to the key function of FOXP2 in both
lung and brain development.
It is also supportive that we identified consensus sites
described elsewhere on the basis of the binding structure
of FOXP244 in a majority of the FOXP2 target genes. Sta-
tistical analysis supports the enrichment of putative
FOXP2 binding sites within the target genes identified in
BG. However, there was only a trend toward significance
in frontal cortex and lung, and not all candidate genes
identified have a consensus binding sequence, suggesting
that other as-yet unidentified FOXP2 regulatory regions
exist in these genes or that FOXP2 may act in a complex
that permits binding to different sites. These results in-
dicate the need for further investigation into the se-
quence-specific DNA binding parameters of FOXP2.
Here, we took an additional validation step by showing
that 125% of genes whose promoters were bound by
FOXP2 protein were indeed regulated by manipulation of
FOXP2 levels in a neuronal cell line. Since the basic ChIP
experiment was done in tissue, and it was necessary to
perform functional confirmation in vitro, the cell line is
distinct from the original in vivo tissue; yet, we were still
able to confirm transactivation in a percentage of targets
very similar to that in other published studies.39,40,42,43 We
were able to show that, in general, overexpression of
FOXP2 resulted in the expected decrease in expression of
target genes. However, overexpression of FOXP2 increased
expression of TAGLN, CALCRL, and CER1, suggesting tran-
scriptional activation. This, along with the study by Ver-
nes et al.,19(in this issue) provides the first evidence that FOXP2
can potentially act as a transcriptional activator in certain
situations. ChIP-chip identifies promoter regions that are
bound to FOXP2 but does not indicate more-complex
transcriptional regulation that may have tissue- and cell-
specific requirements for regulating transcription. Thus,
the behavior of the subset of genes not altered after forced
FOXP2 overexpression may be attributed to the lack of
additional binding partners necessary for FOXP2 tran-
scriptional regulation of certain genes. However, we do
expect a percentage of false-positive results contained
within our subset of genes.
Using a similar experimental paradigm, Vernes et al.19(in
this issue) identified FOXP2 targets in vitro in SH-SY5Y cells
by using a commercial antibody that recognizes a different
region of the FOXP2 protein and found 303 FOXP2 tar-
gets. Of our core set of 34 targets that we found in vivo
in both IFC and BG, 47% (16) overlap the targets identified
in SH-SY5Y cells by Vernes et al., and there is a 22% over-
lap between all 285 genes we identified in either IF or BG
and the 303 genes that Vernes et al. identified in SY5Y (62
of 285). This highly significant overlap provides another
level of independent confirmation of our results, and our
data speak to the relevance of at least a subset of the in
vitro findings for normal human brain development in
vivo. Vernes et al. also found up-regulation of certain tar-
gets’ expression after FOXP2 overexpression, consistent
with the notion that some targets may not be repressed.
Although we each confirmed that FOXP2 binding regu-
lates the targets identified, and both studies note down-
regulation of HSP7 and PM5 with FOXP2 expression in
SH-SY5Y cells, in some cases, such as for CALCRL, we ob-
served different directions of regulation in vitro after
FOXP2 overexpression than did Vernes et al. Testing the
possibility that this difference could be the result of iden-
tification of different isoforms, each group tested both
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CALCRL primer pairs on our respective cDNA. The results
were consistent across primer pairs in each cell line and
therefore are not due to testing distinct isoforms (data not
shown). Many factors could explain these differences be-
tween the studies. For example, variations in the levels of
FOXP2 expression in each of the cell lines used could ex-
plain these discrepancies. SH-SY5Y cells also contain abun-
dant amounts of FOXP1 protein, and it is possible that
FOXP2 and FOXP1 share a subset of common transcrip-
tional targets. FOXP2 has been shown to heterodimerize
with FOXP1,13 and heterodimers of FOXP2 with FOXP1
may result in different transcriptional outcomes than
homodimers of FOXP2 or FOXP1. Thus, one could imag-
ine a scenario in which low levels of FOXP2 repress tran-
scription through heterodimerization with FOXP1, but,
with increasing amounts of FOXP2, there is competition
of FOXP2 homodimers with endogenous FOXP1, leading
to transcriptional activation. Thus, as has been the case
with other transcription factors, it will be important to
define a subset of genes coregulated by FOXP2 and FOXP1,
as well as the repertoire of FOXP2 partners and their reg-
ulation, to understand the context in which FOXP2 acts
as a transcriptional repressor or activator.
Function of Targets
The target genes identified provide a foundation for ex-
ploring the transcriptional network downstream of FOXP2
in the developing brain. Functions such as growth regu-
lation, embryonic development, and signal transduction
identified as enriched GO categories for the candidate tar-
gets of FOXP2 are also common functions for targets of
other forkhead-containing genes.62–64 GO analysis of the
potential targets specific to IFC indicated that many of
these genes are involved in growth and morphogenesis,
whereas other classes, such as development, were enriched
for in targets identified in BG, indicating different down-
stream functional differences in the different regions of
the brain. Furthermore, FOXP2 continues to be expressed
in the adult and is modulated by vocal learning in adult
song birds.55 Thus, the identification of FOXP2 target
genes involved in neurite outgrowth, calcium signaling,
and learning, by Ingenuity pathway analysis, may provide
a potential molecular link to ongoing behavioral plasticity
throughout development and into adulthood.
Previous work has suggested that FOXP2 may be under
positive selection in humans, so we reasoned that some
FOXP2 targets may be components of neurodevelopmen-
tal pathways also under positive selection.17,18 Large-scale
gene coexpression network analysis of human and chim-
panzee brain confirmed the previously reported action of
positive selection on the pathway of the electron transport
chain.57,65–67 Further, this work showed that entire func-
tional modules of coexpressed genes appear to be under
positive selection in humans.65 Other genomewide anal-
yses investigating alleles with accelerated increase of fre-
quency between three different human populations have
demonstrated that multiple genes in the phosphatidyli-
nositol pathway, in addition to the electron transport
chain pathway, have undergone positive selection.68 These
precedents support the notion that positive selection of
genes regulated by FOXP2 may direct us to molecular
pathways of particular interest in human evolution and
human cognitive specialization, since language is a com-
plex trait that likely can be modulated by many genes.11
Some of the FOXP2 target genes that we identified are
genes known to be involved in human brain development
and patterning, such as EFNB3, HESX1, and CER1. This
provides further support for the notion that targets of
FOXP2 showing these significant differences between hu-
mans and our closest relative, the chimpanzee, are par-
ticularly important in development of human cognitive
specializations.
Similarly, 15 of the potential FOXP2 targets identified
here (APOD,69 CCK,70,71 CCK-AR,72–75 CCND2,76 CD5,77,78
DISC1,79–81 DRD2,82 GABBR1,83 MT2A,84 NOS1,85–87
PMX2B,88 TDO2,89 TIMELESS,90 WNT1,91 and ZNF7492)
have shown some evidence of association with schizo-
phrenia (SCZD [MIM 181500]), a disease that has been
suggested to involve primary language dysfunction. Al-
though most of these associations are preliminary or mar-
ginal, DISC1 has been clearly replicated. The association
of SNP rs2396753, located within an intron of FOXP2,
with schizophrenia with auditory hallucinations,93 further
suggests that targets of FOXP2 may also be candidates for
involvement in schizophrenia. The concept that complex
genetic disorders might involve multiple genes within
common pathways implies that the FOXP2 targets iden-
tified here are realistic candidates for a variety of neuro-
developmental disorders involving higher cognitive
functions.
In summary, these data are the first identification of
human FOXP2 targets in the developing brain. This is also
the first time, to our knowledge, that ChIP-chip has been
used to assess transcription factor targets in the human
fetal brain. Many of the identified FOXP2 targets have
been previously characterized as having critical roles in
several important neuronal features, such as neurite out-
growth and axon pathfinding. In addition, we have un-
covered targets of FOXP2 that may have vital functions
in the evolution of the mammalian brain. Since FOXP2
has a direct link to speech in humans, together these find-
ings provide insight into signaling pathways that may be
important both in the development and evolution of
language.
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